Rusan Pharma Ltd., which is into ache administration and deaddiction options worldwide, has introduced the revealing of its second API manufacturing facility in Pithampur, Special Economic Zone (SEZ), in Madhya Pradesh.
The firm is investing ₹300 crore to make this plant operational in two phases in 2024. The part one is predicted to go dwell in January 2024.
Navin Saxena, Founder and Chairman, Rusan Pharma, stated, “The new API facility will enable us to significantly enhance our existing API capacity and ensure the security of supply of critical APIs to meet the growing demand for our addiction treatment and pain management products in India and globally.”
“The company has invested the last 30 years and pioneered in making the treatment of addiction acceptable and accessible. We firmly believe that access to quality healthcare is a right and not a privilege. Our goal is to ensure that everyone who seeks treatment for addiction and pain management can access it,” Dr. Saxena stated.
The new facility will capitalise on the help and subsidies supplied by the Madhya Pradesh state authorities. This central location will streamline enterprise operations and export processes by the dry port, making it an optimum selection for Rusan Pharma’s growth plans, the corporate stated.
Kunal Saxena, Managing Director, Rusan Pharma stated, “With an investment of about ₹300 crore in two phases, this new API facility will increase our current API manufacturing capacity from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur.”
“Our new plant boasts five modular API manufacturing blocks with dedicated suites for finished API manufacturing. This grants us complete control over the quality of our products and reduces our dependency on imports, aligning perfectly with our commitment to excellence,” he stated.
“Incorporating advanced automation and compliant software will help us move towards paperless manufacturing, along with stringent environmental controls, which will enable us to produce essential medicines more affordably, expanding accessibility to a broader population,” he added.
Rusan’s present GMP approvals for its APIs and completed formulations amenities have the potential to cater to 90% of the world’s demand. Some of the GMP approvals they’re accredited with are Health Canada, TGA-Australia, SAPHRA-South Africa, EU, UAE, and Russia, to call just a few, the corporate stated.
The facility is designed to fulfill stringent worldwide regulatory pointers, guaranteeing the best stage of compliance. With the manufacturing functionality of 400 metric tonnes of APIs yearly, the ability considerably contributes to Rusan Pharma’s progress and growth plans, diversifying its portfolio and increasing its attain in India and different markets, it added.
